美诺华: 宁波美诺华药业股份有限公司关于全资子公司获得枸橼酸莫沙必利片药品注册证书的公告

Group 1 - The company’s subsidiary, Ningbo Meinuo Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration, allowing it to produce and sell the drug in the domestic market [1][2] - The drug is indicated for improving gastrointestinal symptoms caused by reduced gastrointestinal motility, such as functional dyspepsia and chronic gastritis [1] - The global sales forecast for Mosapride Citrate Tablets in 2024 is approximately $16.53 million, with China accounting for about $5.28 million of that total [1] Group 2 - The approval of the drug enhances the company's market competitiveness and enriches its gastrointestinal product pipeline, positively impacting its operational development [2] - The future sales of the drug may be influenced by various uncertain factors, including policy changes, market demand, and competition from similar products [2]